Literature DB >> 1733436

A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid.

J H Anderson1, D J Kerr, A Setanoians, T G Cooke, C S McArdle.   

Abstract

Recent clinical trials have suggested that a combination of folinic acid and 5-fluorouracil (5-FU) may improve response rates and survival in patients with advanced colorectal cancer. However, this regimen has been complicated by potentially life threatening toxicity. Regional delivery of folinic acid via a hepatic artery catheter might be expected to reduce systemic exposure and subsequent adverse effects. The present study compared the pharmacokinetic profiles of intravenous and intra-hepatic arterial infusions of folinic acid in patients with colorectal liver metastases (n = 6) who were being treated with weekly regional infusions of 5-FU. The mean area under the plasma concentration--time curve, the peak plasma concentration and the steady state volume of distribution were 163 micrograms ml-1 h-1 (SD 41), 18.5 micrograms ml-1 (SD 1.2) and 7.41 m-2 (SD 0.44) respectively following intravenous administration of folinic acid compared with 142 micrograms ml-1 h-1 (SD 45), 14.8 micrograms ml-1 (SD 2.4) and 11.21 m-2 (SD 1.22) following intra-hepatic arterial administration (P less than 0.05). Regional folinic acid was therefore associated with a statistically significant reduction in systemic exposure compared with the intravenous route.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1733436      PMCID: PMC1977354          DOI: 10.1038/bjc.1992.26

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  11 in total

1.  5-Fluorouracil (FUra) and folinic acid (FA) therapy in patients with colorectal cancer.

Authors:  C Erlichman
Journal:  Adv Exp Med Biol       Date:  1988       Impact factor: 2.622

Review 2.  The systemic chemotherapy of hepatic metastases.

Authors:  N Kemeny
Journal:  Semin Oncol       Date:  1983-06       Impact factor: 4.929

Review 3.  Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.

Authors:  M A Poon; M J O'Connell; C G Moertel; H S Wieand; S A Cullinan; L K Everson; J E Krook; J A Mailliard; J A Laurie; L K Tschetter
Journal:  J Clin Oncol       Date:  1989-10       Impact factor: 44.544

4.  Prospective randomized controlled trial of hepatic arterial embolization or infusion chemotherapy with 5-fluorouracil and degradable starch microspheres for colorectal liver metastases.

Authors:  T M Hunt; A D Flowerdew; S J Birch; J D Williams; M A Mullee; I Taylor
Journal:  Br J Surg       Date:  1990-07       Impact factor: 6.939

5.  Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma.

Authors:  F Trave; Y M Rustum; N J Petrelli; L Herrera; A Mittelman; C Frank; P J Creaven
Journal:  J Clin Oncol       Date:  1988-07       Impact factor: 44.544

6.  Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects.

Authors:  J A Straw; D Szapary; W T Wynn
Journal:  Cancer Res       Date:  1984-07       Impact factor: 12.701

7.  Hepatic resection for colorectal secondaries.

Authors:  N D Karanjia; M Rees; D Schache; R J Heald
Journal:  Br J Surg       Date:  1990-01       Impact factor: 6.939

8.  Pharmacokinetics of leucovorin calcium after intravenous, intramuscular, and oral administration.

Authors:  B W McGuire; L L Sia; P T Leese; M L Gutierrez; E L Stokstad
Journal:  Clin Pharm       Date:  1988-01

Review 9.  5-Fluorouracil and folinic acid: interesting biochemistry or effective treatment?

Authors:  D J Kerr
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640

10.  The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.

Authors:  J A Goldberg; D J Kerr; D G Watson; N Willmott; C D Bates; J H McKillop; C S McArdle
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

View more
  6 in total

1.  Suppository delivery of 5-fluorouracil in rectal cancer.

Authors:  S Galandiuk; W Wrightson; L Marr; S Myers; R V LaRocca
Journal:  Ann Surg Oncol       Date:  1996-05       Impact factor: 5.344

Review 2.  Clinical pharmacokinetic advantages of new drug delivery methods for the treatment of liver tumours.

Authors:  J H Anderson; H W Warren; C S McArdle
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

3.  A phase I study of regional 5-fluorouracil and systemic folinic acid for patients with colorectal liver metastases.

Authors:  J H Anderson; D J Kerr; T G Cooke; C S McArdle
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

Review 4.  Hepatic arterial chemotherapy for metastatic colorectal carcinoma.

Authors:  P G de Takats; D J Kerr; C J Poole; H W Warren; C S McArdle
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

5.  A phase II study of regional 5-fluorouracil infusion with intravenous folinic acid for colorectal liver metastases.

Authors:  H W Warren; J H Anderson; P O'Gorman; E Kane; D J Kerr; T G Cooke; C S McArdle
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

6.  Development of in situ gelling and bio adhesive 5-Fluorouracil enema.

Authors:  Lu-Lu Wang; Wen-Sheng Zheng; Shao-Hua Chen; Xia-Qin Fang
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.